PEMBROLIZUMAB for Malignant melanoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 3,261 adverse event reports in the FDA FAERS database where PEMBROLIZUMAB was used for Malignant melanoma.
Most Reported Side Effects for PEMBROLIZUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Malignant neoplasm progression | 10,111 | 12.1% | 5,124 | 3,426 |
| Death | 4,744 | 5.7% | 4,737 | 893 |
| Diarrhoea | 4,251 | 5.1% | 556 | 2,141 |
| Fatigue | 3,833 | 4.6% | 365 | 1,246 |
| Off label use | 3,416 | 4.1% | 747 | 1,045 |
| Product use in unapproved indication | 3,191 | 3.8% | 514 | 909 |
| Pyrexia | 3,155 | 3.8% | 444 | 2,194 |
| Rash | 2,900 | 3.5% | 289 | 1,047 |
| Nausea | 2,670 | 3.2% | 335 | 1,237 |
| Decreased appetite | 2,486 | 3.0% | 371 | 1,235 |
| Hypothyroidism | 2,326 | 2.8% | 242 | 935 |
| Product use issue | 2,323 | 2.8% | 417 | 610 |
| Hypertension | 2,245 | 2.7% | 276 | 1,118 |
| Asthenia | 2,131 | 2.5% | 300 | 1,058 |
| Interstitial lung disease | 2,113 | 2.5% | 869 | 1,276 |
Other Indications for PEMBROLIZUMAB
Non-small cell lung cancer (6,893)
Triple negative breast cancer (5,148)
Endometrial cancer (4,343)
Lung adenocarcinoma (3,954)
Lung neoplasm malignant (3,575)
Renal cell carcinoma (3,027)
Metastatic malignant melanoma (2,742)
Uterine cancer (2,223)
Product used for unknown indication (2,091)
Transitional cell carcinoma (1,951)
Other Drugs Used for Malignant melanoma
NIVOLUMAB (10,599)
IPILIMUMAB (8,903)
DABRAFENIB (5,277)
TRAMETINIB DIMETHYL SULFOXIDE (3,841)
BINIMETINIB (2,613)
ENCORAFENIB (2,591)
VEMURAFENIB (2,548)
TRAMETINIB (1,448)
COBIMETINIB (1,324)
TALIMOGENE LAHERPAREPVEC (562)